1.Study of application of Common Data Model of Observational Medical Outcomes Partnership in China
Meng ZHANG ; Peng SHEN ; Zhike LIU ; Van Zandt MUI ; Jing LI ; Chao LI ; Yexiang SUN ; Junqing XIE ; Hripcsak GEORGE ; Yong CHEN ; Hongbo LIN ; Siyan ZHAN ; Feng SUN
Chinese Journal of Epidemiology 2025;46(5):907-913
Objective:To comprehensively evaluate the application of Common Data Model (CDM) of Observational Medical Outcomes Partnership (OMOP) in China, and provide reference for the implementation of data standardization and evidence sharing in China.Methods:PubMed, Embase, Web of Science, CNKI, VIP, WanFang and SinoMed databases were used for literature retrieval to collect the research papers of OMOP CDM application for data standardization in China until March 15, 2023. The information about institutions, types and numbers of patients were extracted.Results:A total of 14 research papers, including 9 in English and 5 in Chinese, were selected. The research papers published since 2018 were collected, which focused on patients with hypertension, diabetes, and depression. A total of 12 institutions or platforms transformed data into OMOP CDM. Jiangsu Provincial People's Hospital was the first one to apply the CDM and demonstrated its feasibility in China. Additionally, the regional information system in Yinzhou District of Ningbo, Zhejiang Province, standardized the multi-dimensional data of patients with diabetes and hypertension. Based on this platform, a series of prediction models for complications in patients with diabetes were constructed. Another major database in Beijing Anding Hospital applied OMOP CDM to analyze the characteristics of patients with late-life depression and dementia.Conclusions:This study analyzed the application of OMOP CDM in China. Through in-depth analysis of specific cases, the study provided guidance for the future cross-regional evidence sharing and collaboration.
2.Guideline for Adult Weight Management in China
Weiqing WANG ; Qin WAN ; Jianhua MA ; Guang WANG ; Yufan WANG ; Guixia WANG ; Yongquan SHI ; Tingjun YE ; Xiaoguang SHI ; Jian KUANG ; Bo FENG ; Xiuyan FENG ; Guang NING ; Yiming MU ; Hongyu KUANG ; Xiaoping XING ; Chunli PIAO ; Xingbo CHENG ; Zhifeng CHENG ; Yufang BI ; Yan BI ; Wenshan LYU ; Dalong ZHU ; Cuiyan ZHU ; Wei ZHU ; Fei HUA ; Fei XIANG ; Shuang YAN ; Zilin SUN ; Yadong SUN ; Liqin SUN ; Luying SUN ; Li YAN ; Yanbing LI ; Hong LI ; Shu LI ; Ling LI ; Yiming LI ; Chenzhong LI ; Hua YANG ; Jinkui YANG ; Ling YANG ; Ying YANG ; Tao YANG ; Xiao YANG ; Xinhua XIAO ; Dan WU ; Jinsong KUANG ; Lanjie HE ; Wei GU ; Jie SHEN ; Yongfeng SONG ; Qiao ZHANG ; Hong ZHANG ; Yuwei ZHANG ; Junqing ZHANG ; Xianfeng ZHANG ; Miao ZHANG ; Yifei ZHANG ; Yingli LU ; Hong CHEN ; Li CHEN ; Bing CHEN ; Shihong CHEN ; Guiyan CHEN ; Haibing CHEN ; Lei CHEN ; Yanyan CHEN ; Genben CHEN ; Yikun ZHOU ; Xianghai ZHOU ; Qiang ZHOU ; Jiaqiang ZHOU ; Hongting ZHENG ; Zhongyan SHAN ; Jiajun ZHAO ; Dong ZHAO ; Ji HU ; Jiang HU ; Xinguo HOU ; Bimin SHI ; Tianpei HONG ; Mingxia YUAN ; Weibo XIA ; Xuejiang GU ; Yong XU ; Shuguang PANG ; Tianshu GAO ; Zuhua GAO ; Xiaohui GUO ; Hongyi CAO ; Mingfeng CAO ; Xiaopei CAO ; Jing MA ; Bin LU ; Zhen LIANG ; Jun LIANG ; Min LONG ; Yongde PENG ; Jin LU ; Hongyun LU ; Yan LU ; Chunping ZENG ; Binhong WEN ; Xueyong LOU ; Qingbo GUAN ; Lin LIAO ; Xin LIAO ; Ping XIONG ; Yaoming XUE
Chinese Journal of Endocrinology and Metabolism 2025;41(11):891-907
Body weight abnormalities, including overweight, obesity, and underweight, have become a dual public health challenge in Chinese adults: overweight and obesity lead to a variety of chronic complications, while underweight increases the risks of malnutrition, sarcopenia, and organ dysfunction. To systematically address these issues, multidisciplinary experts in endocrinology, sports science, nutrition, and psychiatry from various regions have held multiple weight management seminars. Based on the latest epidemiological data and clinical evidence, they expanded the guideline to include assessment and intervention strategies for underweight, in addition to the core content of obesity management. This guideline outlines the etiological mechanisms, evaluation methods, and multidimensional management strategies for overweight and obesity, covering key areas such as diagnosis and assessment, medical nutrition therapy, exercise prescription, pharmacological intervention, and psychological support. It is intended to provide a scientific and standardized approach to weight management across the adult population, aiming to curb the rising prevalence of obesity, mitigate complications associated with abnormal body weight, and improve nutritional status and overall quality of life.
3.Incidence and Mortality of Gastric Cancer in Hefei City of Anhui Province in 2020 and the Trend from 2013 to 2020
Jiajia LI ; Xiaopeng ZHANG ; Junqing ZHANG ; Feng SUN
China Cancer 2025;34(6):464-470
[Purpose]To analyze the incidence and mortality of gastric cancer in Hefei City of Anhui Province in 2020 and the trend from 2013 to 2020.[Methods]The incidence and mortality data of gastric cancer in Hefei City from 2013 to 2020 were collected from sofeware CanReg4.The incidence(mortality)rate,age-standardized incidence(mortality)rate by Chinese standard popula-tion and world standard population(ASIRC/ASIRW,ASMRC/ASMRW),age-specific incidence(mortality)rate and average annual percentage change(AAPC)of the incidence(mortality)rate were calculated.[Results]In 2020,the crude incidence rate of gastric cancer in Hefei was 47.14/105,the ASIRC was 27.10/105,the ASIRW was 26.78/105,ranking the second in all cancer types.The crude mortality rate of gastric cancer was 41.12/105,the ASMRC was 21.64/105,the ASMRW was 21.25/105,ranking the second in all cancer types.The incidence rate and mortality rate of gastric cancer increased with age,and reached the peak in the age group of 80~84 years old.The incidence rate and mortality rate of men were higher than those of women,and rates in rural areas were higher than those in urban areas.The ASIRC and ASMRC of gastric cancer showed downward trends from 2013 to 2020 in Hefei(AAPC were-7.19%and-4.71%,both P<0.05).[Conclusion]The ASIRC and ASMRC of gastric cancer show downward trends from 2013 to 2020 in Hefei,but are still higher than the average level in China,so the prevention and control work should be fur-ther strengthened.
4.Study of application of Common Data Model of Observational Medical Outcomes Partnership in China
Meng ZHANG ; Peng SHEN ; Zhike LIU ; Van Zandt MUI ; Jing LI ; Chao LI ; Yexiang SUN ; Junqing XIE ; Hripcsak GEORGE ; Yong CHEN ; Hongbo LIN ; Siyan ZHAN ; Feng SUN
Chinese Journal of Epidemiology 2025;46(5):907-913
Objective:To comprehensively evaluate the application of Common Data Model (CDM) of Observational Medical Outcomes Partnership (OMOP) in China, and provide reference for the implementation of data standardization and evidence sharing in China.Methods:PubMed, Embase, Web of Science, CNKI, VIP, WanFang and SinoMed databases were used for literature retrieval to collect the research papers of OMOP CDM application for data standardization in China until March 15, 2023. The information about institutions, types and numbers of patients were extracted.Results:A total of 14 research papers, including 9 in English and 5 in Chinese, were selected. The research papers published since 2018 were collected, which focused on patients with hypertension, diabetes, and depression. A total of 12 institutions or platforms transformed data into OMOP CDM. Jiangsu Provincial People's Hospital was the first one to apply the CDM and demonstrated its feasibility in China. Additionally, the regional information system in Yinzhou District of Ningbo, Zhejiang Province, standardized the multi-dimensional data of patients with diabetes and hypertension. Based on this platform, a series of prediction models for complications in patients with diabetes were constructed. Another major database in Beijing Anding Hospital applied OMOP CDM to analyze the characteristics of patients with late-life depression and dementia.Conclusions:This study analyzed the application of OMOP CDM in China. Through in-depth analysis of specific cases, the study provided guidance for the future cross-regional evidence sharing and collaboration.
5.Incidence and Mortality of Thyroid Cancer in Hefei City,Anhui Province in 2021 and the Trend from 2013 to 2021
Jiajia LI ; Xiaopeng ZHANG ; Junqing ZHANG ; Feng SUN ; Xiaoru LI
China Cancer 2025;34(3):188-194
[Purpose]To analyze the incidence and mortality of thyroid cancer in Hefei of Anhui Province in 2021 and the trend from 2013 to 2021.[Methods]Using the data of Hefei Cancer Registry,the crude incidence/mortality rate,age-standardized incidence/mortality rate by Chinese standard population(ASIRC/ASMRC)and world standard population(ASIRW/ASMRW)were cal-culated in 2021.The average annual percentage change(AAPC)of the crude incidence/mortality rate and age-standardized incidence/mortality rate were calculated using Joinpoint software to ana-lyze trends from 2013 to 2021.[Results]In 2021,the crude incidence rate of thyroid cancer in Hefei was 47.54/105,the ASIRC was 42.30/105,the ASIRW was 35.85/105.The crude mortality rate of thyroid cancer was 0.70/105,the ASMRC was 0.38/105,the ASMRW was 0.40/105.The in-cidence rate of thyroid cancer reached its peak in the 50~54 age group and the mortality rate reached its peak in the group over 85 years old.The incidence rate and mortality rate of women were higher than those of men,and the incidence and mortality rates in urban areas were higher than those in rural areas.The incidence and mortality of thyroid cancer showed a upward trend from 2013 to 2021 in Hefei City(AAPC were 38.23%and 9.68%,both P<0.05).[Conclusion]The ASIRC/ASMRC of thyroid cancer showed a upward trend from 2013 to 2021 in Hefei City.It is necessary to strengthen prevention and control to reduce the exposure of risk factors.At the same time,diagnosis and treatment should be standardized to avoid over diagnosis.
6.Incidence and Mortality of Thyroid Cancer in Hefei City,Anhui Province in 2021 and the Trend from 2013 to 2021
Jiajia LI ; Xiaopeng ZHANG ; Junqing ZHANG ; Feng SUN ; Xiaoru LI
China Cancer 2025;34(3):188-194
[Purpose]To analyze the incidence and mortality of thyroid cancer in Hefei of Anhui Province in 2021 and the trend from 2013 to 2021.[Methods]Using the data of Hefei Cancer Registry,the crude incidence/mortality rate,age-standardized incidence/mortality rate by Chinese standard population(ASIRC/ASMRC)and world standard population(ASIRW/ASMRW)were cal-culated in 2021.The average annual percentage change(AAPC)of the crude incidence/mortality rate and age-standardized incidence/mortality rate were calculated using Joinpoint software to ana-lyze trends from 2013 to 2021.[Results]In 2021,the crude incidence rate of thyroid cancer in Hefei was 47.54/105,the ASIRC was 42.30/105,the ASIRW was 35.85/105.The crude mortality rate of thyroid cancer was 0.70/105,the ASMRC was 0.38/105,the ASMRW was 0.40/105.The in-cidence rate of thyroid cancer reached its peak in the 50~54 age group and the mortality rate reached its peak in the group over 85 years old.The incidence rate and mortality rate of women were higher than those of men,and the incidence and mortality rates in urban areas were higher than those in rural areas.The incidence and mortality of thyroid cancer showed a upward trend from 2013 to 2021 in Hefei City(AAPC were 38.23%and 9.68%,both P<0.05).[Conclusion]The ASIRC/ASMRC of thyroid cancer showed a upward trend from 2013 to 2021 in Hefei City.It is necessary to strengthen prevention and control to reduce the exposure of risk factors.At the same time,diagnosis and treatment should be standardized to avoid over diagnosis.
7.Incidence and Mortality of Gastric Cancer in Hefei City of Anhui Province in 2020 and the Trend from 2013 to 2020
Jiajia LI ; Xiaopeng ZHANG ; Junqing ZHANG ; Feng SUN
China Cancer 2025;34(6):464-470
[Purpose]To analyze the incidence and mortality of gastric cancer in Hefei City of Anhui Province in 2020 and the trend from 2013 to 2020.[Methods]The incidence and mortality data of gastric cancer in Hefei City from 2013 to 2020 were collected from sofeware CanReg4.The incidence(mortality)rate,age-standardized incidence(mortality)rate by Chinese standard popula-tion and world standard population(ASIRC/ASIRW,ASMRC/ASMRW),age-specific incidence(mortality)rate and average annual percentage change(AAPC)of the incidence(mortality)rate were calculated.[Results]In 2020,the crude incidence rate of gastric cancer in Hefei was 47.14/105,the ASIRC was 27.10/105,the ASIRW was 26.78/105,ranking the second in all cancer types.The crude mortality rate of gastric cancer was 41.12/105,the ASMRC was 21.64/105,the ASMRW was 21.25/105,ranking the second in all cancer types.The incidence rate and mortality rate of gastric cancer increased with age,and reached the peak in the age group of 80~84 years old.The incidence rate and mortality rate of men were higher than those of women,and rates in rural areas were higher than those in urban areas.The ASIRC and ASMRC of gastric cancer showed downward trends from 2013 to 2020 in Hefei(AAPC were-7.19%and-4.71%,both P<0.05).[Conclusion]The ASIRC and ASMRC of gastric cancer show downward trends from 2013 to 2020 in Hefei,but are still higher than the average level in China,so the prevention and control work should be fur-ther strengthened.
8.Guideline for Adult Weight Management in China
Weiqing WANG ; Qin WAN ; Jianhua MA ; Guang WANG ; Yufan WANG ; Guixia WANG ; Yongquan SHI ; Tingjun YE ; Xiaoguang SHI ; Jian KUANG ; Bo FENG ; Xiuyan FENG ; Guang NING ; Yiming MU ; Hongyu KUANG ; Xiaoping XING ; Chunli PIAO ; Xingbo CHENG ; Zhifeng CHENG ; Yufang BI ; Yan BI ; Wenshan LYU ; Dalong ZHU ; Cuiyan ZHU ; Wei ZHU ; Fei HUA ; Fei XIANG ; Shuang YAN ; Zilin SUN ; Yadong SUN ; Liqin SUN ; Luying SUN ; Li YAN ; Yanbing LI ; Hong LI ; Shu LI ; Ling LI ; Yiming LI ; Chenzhong LI ; Hua YANG ; Jinkui YANG ; Ling YANG ; Ying YANG ; Tao YANG ; Xiao YANG ; Xinhua XIAO ; Dan WU ; Jinsong KUANG ; Lanjie HE ; Wei GU ; Jie SHEN ; Yongfeng SONG ; Qiao ZHANG ; Hong ZHANG ; Yuwei ZHANG ; Junqing ZHANG ; Xianfeng ZHANG ; Miao ZHANG ; Yifei ZHANG ; Yingli LU ; Hong CHEN ; Li CHEN ; Bing CHEN ; Shihong CHEN ; Guiyan CHEN ; Haibing CHEN ; Lei CHEN ; Yanyan CHEN ; Genben CHEN ; Yikun ZHOU ; Xianghai ZHOU ; Qiang ZHOU ; Jiaqiang ZHOU ; Hongting ZHENG ; Zhongyan SHAN ; Jiajun ZHAO ; Dong ZHAO ; Ji HU ; Jiang HU ; Xinguo HOU ; Bimin SHI ; Tianpei HONG ; Mingxia YUAN ; Weibo XIA ; Xuejiang GU ; Yong XU ; Shuguang PANG ; Tianshu GAO ; Zuhua GAO ; Xiaohui GUO ; Hongyi CAO ; Mingfeng CAO ; Xiaopei CAO ; Jing MA ; Bin LU ; Zhen LIANG ; Jun LIANG ; Min LONG ; Yongde PENG ; Jin LU ; Hongyun LU ; Yan LU ; Chunping ZENG ; Binhong WEN ; Xueyong LOU ; Qingbo GUAN ; Lin LIAO ; Xin LIAO ; Ping XIONG ; Yaoming XUE
Chinese Journal of Endocrinology and Metabolism 2025;41(11):891-907
Body weight abnormalities, including overweight, obesity, and underweight, have become a dual public health challenge in Chinese adults: overweight and obesity lead to a variety of chronic complications, while underweight increases the risks of malnutrition, sarcopenia, and organ dysfunction. To systematically address these issues, multidisciplinary experts in endocrinology, sports science, nutrition, and psychiatry from various regions have held multiple weight management seminars. Based on the latest epidemiological data and clinical evidence, they expanded the guideline to include assessment and intervention strategies for underweight, in addition to the core content of obesity management. This guideline outlines the etiological mechanisms, evaluation methods, and multidimensional management strategies for overweight and obesity, covering key areas such as diagnosis and assessment, medical nutrition therapy, exercise prescription, pharmacological intervention, and psychological support. It is intended to provide a scientific and standardized approach to weight management across the adult population, aiming to curb the rising prevalence of obesity, mitigate complications associated with abnormal body weight, and improve nutritional status and overall quality of life.
9.Construction of hepatocellular carcinoma prognosis risk model and prediction of immunotherapy efficacy
Junqing LI ; Liangliang REN ; Weiran LIN ; Yiting FENG ; Chaoying LI ; Ying JIANG
Chinese Journal of Immunology 2024;40(7):1422-1430
Objective:To construct a prognostic risk model for hepatocellular carcinoma(HCC),and elucidate the immune characteristics and immunotherapy response in patients with different prognostic stratification.Methods:RNA-seq data of TCGA-LIHC and ICGC(LIRI-JP),and gene microarray data of GSE14520 and GSE54236 in hepatocellular carcinoma,as well as clinical informa-tion of the corresponding samples were downloaded.First,screening of differentially expressed genes in tumor and non-tumor tissue samples from TCGA-LIHC,GSE14520 and GSE54236.For the common differential genes,univariate cox regression analysis was per-formed using TCGA-LIHC data to obtain HCC prognosis-related genes.Five genes were randomly selected as a panel,and the optimal prognostic marker panel was screened among 10 000 panels using Lasso-cox regression analysis combined with a five-fold cross-valida-tion method.TCGA-LIHC data were used as training set to construct the prognostic risk model,and ICGC data were used as validation set to test the model performance.Tumor immune dysfunction and exclusion(TIDE)algorithm and Immunophenotypic score(IPS)were used to predict immunotherapy efficacy in patients in different prognostic groups.Results:Overall survival was significantly lon-ger in low-risk group of HCC patients compared with high-risk group.Tumor proliferation rate,Treg and Th2 cell chemotaxis,stromal remodeling,and pro-tumor cytokines were significantly increased in high-risk patients,while NK cells,Th1 cells,effector cells and endothelial cells were significantly increased in low-risk patients.Immune checkpoint analysis showed that PDCD1,CTLA4 and CD276 were up-regulated in high-risk patients,while PDCD1LG2 was upregulated in low-risk patients.TIDE score and IPS results predicted that patients in low-risk group had better efficacy to immunotherapy.Conclusion:This study constructed a prognostic risk model containing three genes,DNASE1L3,RDH16 and DLGAP5,which can effectively predict the prognosis of HCC patients and assist in clinical decision making for individualized immunotherapy.
10.Simulation design and experimental study of magnetic stimulation coil for robot pigeon.
Menghua XU ; Xin PU ; Ming CHANG ; Yang SONG ; Fuzhe MA ; Ruituo HUAI ; Junqing YANG ; Hui CHANG ; Feng SHAO ; Hui WANG
Journal of Biomedical Engineering 2023;40(1):141-148
To explore the feasibility of applying magnetic stimulation technology to the movement control of animal robots, the influence of coil radius, number of turns and other factors on the intensity, depth and focus of magnetic stimulation was simulated and analyzed for robot pigeons. The coil design scheme was proposed. The coil was placed on the head and one of the legs of the pigeon, and the leg electromyography (EMG) was recorded when magnetic stimulation was performed. Results showed that the EMG was significantly strengthened during magnetic stimulation. With the reduction of the output frequency of the magnetic stimulation system, the output current was increased and the EMG was enhanced accordingly. Compared with the brain magnetic stimulation, sciatic nerve stimulation produced a more significant EMG enhancement response. This indicated that the magnetic stimulation system could effectively modulate the functions of brain and peripheral nerves by driving the coil. This study provides theoretical and experimental guidance for the subsequent optimization and improvement of practical coils, and lays a preliminary theoretical and experimental foundation for the implementation of magnetic stimulation motion control of animal robots.
Animals
;
Columbidae
;
Robotics
;
Motion
;
Brain
;
Magnetic Phenomena

Result Analysis
Print
Save
E-mail